Nuclear Medicine Advances Span Prostate Cancer, Stroke, and Diabetes

New research published ahead of print in The Journal of Nuclear Medicine—released October 9, 2026—showcases how nuclear medicine and theranostics are evolving across prostate cancer, breast cancer, stroke, and type 1 diabetes. The Society of Nuclear Medicine and Molecular Imaging highlighted studies ranging from matched imaging-and-therapy agents to methods that sharpen contrast and new data on long-term safety. A key report pairs a PSMA-targeting diagnostic agent with a therapeutic compound designed to bind the same prostate-specific membrane antigen target. In mouse models, the therapy accumulated in tumors at 2.2 to 3.5 times higher levels than a reference treatment while producing similar tumor-growth effects. Another study uses an enzyme, carboxypeptidase G2, to reduce radioactive background in blood, boosting the tumor-to-blood imaging signal by more than 40%.